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Objectives
To overcome the still not sufficient implantation rate
following in vitro fertilization (IVF) and intracytoplas-
matic sperm injection (ICSI) in humans, more than two
embryos are commonly replaced, potentially leading to
high number of multiple pregnancies with associated
significantly elevated risks like low birth weight.
One of the solutions for avoiding multiple pregnancies
could be optimalization of embryo selection and single
embryo transfer [1]. The traditional systems for assessing
gamete and embryo viability have limited ability to accu-
rately select those with best developmental potential.
Morphological evaluation remains the primary method of
the oocyte and embryo assessment during IVF cycles, but
its modest predictive power and inherent inter- and
intra-observer variability limits its value. Prolonged
embryo culture to blastocyst stage was introduced as a
possible strategy for selecting the best embryos, though
not even this method brought the solution. The extended
period of in-vitro culture may have its side effects – e.g.
predispose the embryo to phenomena such as ‘large off-
spring syndrome’, which is probably linked to altered
gene expression, particularly of imprinted genes.
The unexplained repeated implantation failure (RIF) is
still another unsolved and one of the principal problems
to affect the outcome of assisted reproductive technol-
ogy (ART). The successful embryo implantation requires
accurate temporal regulation of maternal immune func-
tion (to accommodate a semi-allogeneic embryo) and
endocrine system [2]. The past few years have witnessed
a virtual explosion in the identification of gene muta-
tions or polymorphisms that cause or are linked to
human infertility and that are inherited in a polygenic/
multifactorial fashion.
Suggested technologic approaches
The “best viable” embryo selection and also the optimal
implantation regulation, both are going to be solved by
new diagnostics and treatment methods based on persona-
lized omics profiling [3]. Molecules of embryo-endometrial
cross talk that are engaged in regulation of the embryo
implantation and selected components of follicular fluid as
well as embryo media will play a role on a developmental
potential of the embryo and treatment efficiency.
Expected impact if the project will succeed
The goal of our effort is to point out new and potentially
useful biomarkers that can be used for the improvement
of pregnancy rates after the assisted reproduction techni-
ques (ART) in near future and also to emphasize some of
the novel molecular targets and biomarkers that have been
reported recently and might contribute to new strategies
of infertility management that will return a hope of natural
conception for selected couples.
Evaluation of such markers may help clinicians to pre-
dict pregnancy outcome and detect occult implantation
deficiency. Moreover, these novel molecular targets are
expected to apply to the clinical practice from bench to
bedside and improve the implantation efficiency in ART.
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